JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Geschlossen

BrancheGesundheitswesen

7.65 -0.78

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.59

Max

7.91

Schlüsselkennzahlen

By Trading Economics

Einkommen

8M

-25M

Gewinnspanne

-8,121.359

Angestellte

202

EBITDA

9.3M

-26M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+71.63% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

284M

561M

Vorheriger Eröffnungskurs

8.43

Vorheriger Schlusskurs

7.65

Nachrichtenstimmung

By Acuity

18%

82%

29 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Omeros Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Okt. 2025, 15:36 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15. Okt. 2025, 13:27 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15. Okt. 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Peer-Vergleich

Kursveränderung

Omeros Corp Prognose

Kursziel

By TipRanks

71.63% Vorteil

12-Monats-Prognose

Durchschnitt 13.13 USD  71.63%

Hoch 20 USD

Tief 6.269 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Omeros Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.265 / 7.49Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

29 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat